Strong and persistent correlation between baseline and follow-up HIV-DNA levels and residual viremia in a population of naïve patients with more than 4 years of effective antiretroviral therapy  by Parisi, S.G. et al.
RESEARCH NOTE VIROLOGYStrong and persistent correlation between
baseline and follow-up HIV-DNA levels and
residual viremia in a population of naïve
patients with more than 4 years of effective
antiretroviral therapyS. G. Parisi1, L. Sarmati2, S. Andreis1, R. Scaggiante1,
M. Cruciani3, R. Ferretto4, V. Manfrin5, M. Basso1,
M. Andreoni2, C. Mengoli1 and G. Palù1
1) Department of Molecular Medicine, University of Padova,
Padova, 2) Clinical Infectious Diseases, Tor Vergata University,
Rome, 3) Center of Preventive Medicine & HIV Outpatient Clinic,
Verona, 4) Infectious Diseases, Schio Hospital, Schio and 5) Infectious
Diseases, Vicenza Hospital, Vicenza, ItalyAbstractIn a longitudinal study on 181 naïve patients who responded to
therapy (mean follow-up 4 years), high baseline human
immunodeﬁciency virus (HIV)-RNA values correlated with high
levels of cellular HIV-DNA at all time points (p < 0.0001, p 0.045,
p 0.0055, and p 0.0025, respectively) and negatively correlated
with undetectable residual viremia (URV; <2.5 copies/mL) at T1,
T2, and T3 (p 0.026, p 0.0149, and p 0.0002, respectively). Baseline
high HIV-DNA levels predicted the persistence of high values (p
0.0001) and negatively correlated with URV (p 0.0254, p 0.0481,
and p 0.0085). These results suggest that baseline viral load,
cellular HIV-DNA, and URV were strongly correlated over long-
term follow-up of antiretroviral therapy responders.
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p://dx.doi.org/10.1016/j.cmi.2014.10.009IntroductionA few data concerning long-term human immunodeﬁciency
virus (HIV)-DNA monitoring have been reported [1–7] and it
is not known how the demonstrated correlations between HIV-
DNA levels and the main viro-immunological parameters could
change over the course of effective treatment. The purpose of
our study was to determine correlations between baseline HIV-
RNA, cellular HIV-DNA, undetectable residual viremia (URV,
<2.5 copies/mL), CD4 count, and acute or chronic infection at
the start of antiretroviral therapy (ART) in naïve patients who
responded to ART.MethodsA longitudinal study was conducted on 181 subjects who ach-
ieved and maintained suppression of HIV-RNA levels
<50 copies/mL for 4 years (mean): plasma HIV-RNA was
determined at least four times per year.
Blood samples were collected at baseline (T0, before the
beginning of therapy, nadir) and at the ﬁrst (T1) and second (T2)
follow-up times. For 70 of the 181 patients, a third follow-up time
(T3) was included. This study was conducted in accordance with
the Helsinki Declaration and local legislation (Ethics Committee
of Padova University Hospital, prot. 2606-12P).
Cellular HIV-DNA and residual viremia (RV) were quantiﬁed
as previously described [1]. A multilevel mixed-effects linear
regression with log10 cellular HIV-DNA as dependent variable
and conventional descriptive statistics were applied when
appropriate.
Most participants were male (76.8%), Italian (80.7%), mean
age of 41 years (±11.5), and 30.9% men who have sex with men,
42.5% heterosexual; patients were mainly chronically infected
(87.3%) and had HIV subtype B (76.8%). Patients’ data were
summarized in Table 1.ResultsA higher CD4 count at each follow-up time was related to a
greater likelihood of having high levels of CD4+ cells at the
subsequent time points (p 0.0001). Fast initial decay of cellular
HIV-DNA levels over time was observed during the ﬁrst 2
years of observation (mean, T1). A slower decay was observed
throughout the study.
High values of plasma HIV-RNA at T0 were correlated with
high levels of cellular HIV-DNA at all time points (p 0.0001, pious Diseases. Published by Elsevier Ltd. All rights reserved
TABLE 1. Evolution of the number and percentage of CD4+ T cells, cellular HIV-DNA levels, and of number of patients with
viremia less of 2.5 copies/mL at T0,T1 and T2 for 181 patients and at T0, T1, T2 and T3 for 70 patients
Laboratory parameters T0 (181 patients) T1 (181 patients) T2 (181 patients) T0 (70 patients) T1 (70 patients) T2 (70 patients) T3 (70 patients)
CD4+ cells/μLa 259 (±174) 563 (±247) 608 (±265) 255 (±176) 560 (±213) 600 (±244) 624 (±241)
CD4+ cells percentagea 15.6 (±8.8) 27.6 (±9.8) 29.6 (±9.1) 16.4 (±8.9) 29.4 (±9.2) 30.3 (±8.6) 31.9 (±8.2)
Cellular HIV-DNA copies/
106 PBMCsa
2942 (±6491) 256.5 (±443) 141.6 (±156.3) 3121 (±4124) 298 (±557) 167.3 (±190.5) 110 (±112)
Plasma log 10 HIV-RNA
a 5.53 (±6.08) <1.69 <1.69 5.57 (±6.11) <1.69 <1.69 <1.69
N (%) of patients with
HIV-RNA <2.5 copies/mL
0 65 (35.9) 62 (34.2) 0 25 (35.7) 25 (35.7) 27 (38.5)
Time of follow-up (months)a 24 ± 12 12 after T1 24 ±12 12 after T1 12 after T2
PBMCs, peripheral blood mononuclear cells.
aMean ± SD.
CMI Parisi et al. HIV-DNA levels and residual viremia 288.e60.045, p 0.0055, and p 0.0025, respectively) and were negatively
correlated with the possibility of reaching URV (p 0.026, p
0.0149, and p 0.0002, respectively). URV at T2 was more
frequently achieved by people beginning with <100 000 copies/
mL than those with >100 000 plasma HIV-RNA copies/mL (p
0.007).
High levels of cellular HIV-DNA at baseline were correlated
with high values of cellular HIV-DNA and were negatively
correlated with the achievement of URV at all follow-up time
points (Table 2).
At T0 (and after 1, 2, 3, and 4 years), a linear correlation
between cellular HIV-DNA and CD4 count was detected;
lower levels of cellular HIV-DNA were detected in patients
with less than 100 000 copies/mL of plasma HIV-RNA at T0.
Primary infection was associated with a lower likelihood of
high levels of cellular HIV-DNA at T1 (p 0.0325), T2 (p 0.0254),
and T3 (p 0.0191); conversely, it was associated with a higher
probability of presenting high levels of CD4+ cells at baseline
(p < 0.0001), T1 (p 0.0006), and T2 (p 0.0011), as well as in
achieving URV at T1 (p 0.0398) and T3 (p 0.0086).
These results were conﬁrmed by a multilevel ME linear
regression, which demonstrated a negative correlation among
DNA values and time, primary infection, and lower RV, and a
positive correlation with CD4 count and baseline plasma RNA
(Supplementary Table 1).TABLE 2. Correlation between achievement of residual plasma vir
viremia at baseline (prior to initiation of ART) and cellular HIV-1 D
HIV-1 RNA <2.5 cps/mL HIV-1 RNA at T0 HIV-1 DNA at T0
At T1 corr −0.1713 −0.1889
p 0.026 0.0254
n 169 140
At T2 corr −0.1882 −0.1692
p 0.0149 0.0481
n 167 137
At T3 corr −0.4921 −0.3919
p 0.0002 0.0085
n 54 44
ART, antiretroviral therapy; HIV, human immunodeﬁciency virus.
Coefﬁcient of correlation (corr), p-value (signiﬁcance), and number of observations (n) are
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InDiscussionThe ﬁrst relevant result of this study was the evidence that the
correlation between the viral load and HIV-DNA at T0 is
steadily maintained over time during effective therapy, con-
ﬁrming that HIV-RNA load and cellular HIV-DNA load are the
main factors related to the size of the viral reservoir, even long
after the beginning of effective therapy.
Second, we showed that high levels of HIV-DNA at all
follow-up times were negatively correlated with the achieve-
ment of URV, suggesting that the persistence of RV is related to
the size of the reservoir.
However, recently, in a cross-sectional study on 243 patients
[8], a high pretreatment viral load was the main factor associ-
ated with the inability to achieve low levels of HIV-DNA after a
long follow-up. In our study, high levels of pretreatment HIV-
RNA were correlated with high levels of HIV-DNA at all
follow-up times, in a longitudinal perspective.
With respect to the work by Fourati et al. [8], based on
multi-experienced patients, our naïve population remained
virologically controlled throughout the study period of 4 years.
In a prospective cohort study [9] a low pre-therapy level of
HIV-DNA was the only predictor of CD4 cell recovery and the
achievement of an undetectable viral load. We conﬁrmed theemia <2.5 cps/mL at T1, T2, and T3 and the values of plasma
NA at baseline, T1, T2, and T3
HIV-1 DNA at T1 HIV-1 DNA at T2 HIV-1 DNA at T3
−0.3107 −0.1544 −0.2181
0.0001 0.0438 0.0762
164 171 67
−0.1902 −0.244 −0.1465
0.0154 0.0014 0.2262
162 168 70
−0.3595 −0.406 −0.5681
0.0088 0.0023 0.0000
52 54 54
reported.
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at all follow-up times. We also found an inverse correlation
between HIV-DNA levels at baseline and at any subsequent
time with the possibility of reaching URV, thus extending the
prognostic signiﬁcance of cellular DNA.
As reported [9], patients with primary infection achieved
lower levels of HIV-DNA and higher levels of CD4+ lympho-
cytes; our study conﬁrms these results on patients without
previous failures, adding data on the highest probability of
achieving URV at different time points.
Recently, no association was found between HIV-DNA
slopes and residual viremia in a longer follow-up, but these
valuable data were based on fewer subjects (n = 18), and need
further elucidations [10].
The main limitation of our study was the evaluation of HIV-
DNA using a PCR-based assay that does not allow the
replication-competent and replication-defective forms of the
viral genome to be distinguished. Nevertheless, unintegrated
HIV-DNA became undetectable during the ﬁrst year of highly
active antiretroviral therapy, and total and integrated HIV-DNA
levels were generally equal in well-controlled patients [11]. Our
study, encompassing a longitudinal perspective with multiple set
points for each patient, suggests that there is a good and long-
lasting correlation between plasma viral load, CD4 count, and
cellular HIV-DNA before and after the start of ART. The amount
of cellular HIV-DNA is predictive of the immune recovery and is
closely related to each other with the control of RV over a long-
term follow-up, in a cohort of naïve and successfully treated
patients. All these correlations are more evident in the popula-
tion of patients treated for a primary infection.Transparency declarationThe authors declare that they have no conﬂicts of interest.AcknowledgementsThis work was supported by MURST ex 60%-2012 and 2013 to S.
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